News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avidia, Inc. Initiates Clinical Trial Of Novel Inhibitor Of Interleukin-6 For Crohn's Disease


9/20/2006 11:28:54 AM

MOUNTAIN VIEW, Calif., Sept. 20 /PRNewswire/ -- Avidia Inc., a privately held biopharmaceutical company, today announced the initiation of and dosing of the first patient for a Phase I clinical trial of its novel drug candidate C326, an inhibitor of interleukin-6 for the treatment of Crohn's disease. C326 is the first in a new class of therapeutic proteins known as Avimer(TM) proteins.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES